Glucagon-like peptide-1 (GLP-1) peptides have emerged as a compelling therapeutic target for managing metabolic conditions. These naturally occurring substances are secreted by the gut in response to meal intake, stimulating insulin release and suppressing glucagon output. GLP-1 agents possess promising therapeutic results in treating type 2 diabet